DEF: Relay Therapeutics Sets Date for 2025 Annual Stockholders Meeting

Relay Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 6, 2025, to elect directors, vote on executive compensation, and ratify the appointment of its independent accounting firm.

Summary

• Relay Therapeutics, Inc. will hold its 2025 Annual Meeting of Stockholders online on June 6, 2025, at 2:00 p.m. Eastern Time.
• Stockholders of record as of April 8, 2025, are entitled to vote at the meeting.
• The meeting will address the election of two class II directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The board recommends voting 'FOR' the election of the director nominees, 'FOR' the advisory vote on executive compensation, and 'FOR' the ratification of the accounting firm appointment.
• The company plans to mail the Notice of Availability of Proxy Materials on or about April 23, 2025.
• To attend the virtual meeting, stockholders must register in advance at www.proxydocs.com/RLAY by June 4, 2025, at 5:00 p.m. Eastern Time.
• The board of directors determined that the company achieved 100% of its corporate goals for 2024.
• The compensation committee determined that the 2024 Performance Criteria were achieved at 98% for each of the named executive officers.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The positive achievement of corporate goals contributes to a slightly positive sentiment.

Positives

• The board of directors recommends voting 'FOR' all proposals.
• The company achieved 100% of its corporate goals for 2024.
• The compensation committee determined that the 2024 Performance Criteria were achieved at 98% for each of the named executive officers.

Future Outlook

The company aims to bring life-changing medicines to patients with the hardest to treat diseases and to push the boundaries of what's possible in drug discovery.

Management Comments

• Sanjiv K. Patel, President and Chief Executive Officer, signed the notice of the 2025 Annual Meeting of Stockholders.

Industry Context

This announcement is a routine part of corporate governance for publicly traded companies, ensuring shareholders have the opportunity to participate in key decisions.

Management Changes

Stakeholder Impact

• Shareholders are asked to vote on key company matters.
• Employees are affected by executive compensation decisions.
• The outcome of the meeting can influence the company's direction and performance, impacting all stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals.
• Stockholders who wish to attend the virtual meeting must register in advance.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, Ernst & Young, Corporate Governance, Relay Therapeutics